

Sri Lanka

Support for Vaccine: Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Sri Lanka

2. **Vaccine grant number:** LKA-IPV-R

3. **Date of Decision Letter:** 14 April 2023

4. **Date of the Partnership Framework Agreement:** 03 April 2014

5. **Programme title:** New Vaccine Support (NVS), Inactivated Polio Vaccine (IPV), Routine, 1 dose

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine:**

IPV, 5 doses/vial, liquid

8. **Programme duration:**¹ 2015-2027

9. **Programme Budget (indicative):**² (subject to the terms of the Partnership Framework Agreement, if applicable)

	2015-2022	2023	2024	2025	2026	2027	Total ³
Programme Budget(US\$)	3.181.231	210.180	338.856	-	-	-	3.730.267

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2015	LKA-IPV-R-VIG-MOH	297.000

11. **Product switch grant:**

Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2015-2022	2023	2024
Number of vaccine doses	-	89.600	144.200
Number of AD syringes	-	438.600	714.600
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	4.400	7.150
Annual Amounts (US\$)	3.181.231	210.180	338.856

13. Procurement agency: UNICEF Supply Division

14. Self-procurement:
Not applicable

15. Co-financing obligations:

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

DocuSigned by:

Amy LaTrielle

62F489252BB7466...

Signed by: Amy LaTrielle

Title: Director, Fragile & Conflict Countries.

OIC for Thabani Maphosa, Managing Director, Country Programmes Delivery

Date: 17 April 2023.